Echo IQ: EchoSolv™

Grow your cardiovascular program through the timely identification of at-risk patients

EchoSolv™ developed by Echo IQ, EchoSolv is a cloud-based decision support platform. Powered by Artificial Intelligence and Machine Learning, it aims to provide physicians with a reliable tool to identify patients at-risk of structural heart disease who may benefit from further referral.

EchoSolv gives physicians access to an easy-to-use dashboard, adjustable alerts, and a deeper view of risk probability to support earlier identification of mortality-risk in patients who might benefit from therapeutic intervention or more proactive vigilance.

Conditions assessed include:

Aortic Stenosis (complete)
Mitral Regurgitation (Q2 2023)

This proprietary cloud-based platform is backed by the latest in medical technology, AI, and machine learning. This innovative decision-support tool is designed to highlight probability indicators for structural heart disease using echocardiographic measurement data from a standard cardiothoracic ultrasound.

Augmented by additional checks and validated in clinical trials, EchoSolv is as comprehensive as it is easy to integrate into your practice.

Request a demo

EchoSolv™ cloud base platform, improving the current standard clinical workflow associated with diagnosis and treatment | Learn more at Hydrix.com

User Friendly Technology

EchoSolv platform is securely built to align with HIPAA and SOC 2 Controls.
Certification Obtained.

Quick view of patient risk probabilities for multiple heart conditions

Set up alerts for instant notification when results warrant fast review

Vendor neutral reporting integration 

Incorporates latest clinical guidelines

<3 sec per result, aiding in efficient diagnosis

Improved Patient Outcomes

Increase accuracy and consistency of diagnosis
Reduce bias in evaluation

EchoSolv is designed to minimise subjectivity in your echo analysis. Our cutting-edge decision support software is aimed to enhance existing clinical workflows, standardise reporting and allow cardiologists to spend more time with their patients.

In additional EcholSolv may highlights patients with Severe AS phenotype who may benefit from further clinical review, facilitating more accurate diagnosis.

Analyses up to 15x more variables

Accelerated Diagnosis

Improve time to treatment
Faster risk assessment

EchoSolv is designed to identify patients having the at-risk phenotype for aortic stenosis, in many cases before they present with any of the current guideline diagnostic thresholds. EchoSolv is 95% accurate in detecting Severe Aortic Stenosis, without relying on left ventricular outflow tract measurements. This level of accuracy allows physicians to identify patients for further referral and to seek out treatment and therapeutic intervention to prevent their risk from developing further. EchoSolv is currently available in the US and Australia, allowing physicians to access in-guideline assessments.

200 million cardiac data points used to develop proprietary algorithm

Trusted Data

Validated solution
AI-powered for deeper insight

A cutting-edge decision-support tool aims to reduce the effects of human cognitive load and improve diagnostic accuracy. This supports physicians and improves patient outcomes.

Backed by leading cardiac data

EchoSolv has been developed using exclusive commercial access to the National Echocardiographic Database of Australia (NEDA). NEDA is a highly trusted and respected research database that collects echocardiographic measurements and associated health information from more than 35 leading hospitals. Most importantly, it is the only database of its size linked to mortality—a critical differentiator for structural heart disease.

200+ million

With over 200 million data points, NEDA provides accurate and important data for diagnosis.

2+ million

We have access to more than 2M cardiac patient records.

18 million deaths

Helping improve more timely medical management for a disease that kills 18 million people annually

EchoSolv™ is currently available in the US and Australia as a guideline-led decision-support tool.
Full phenotyping capabilities will be available pending regulatory approvals.